HPV (Human Papillomavirus) Support Protocol

Infectious Disease/Oncology PreventionLimited Evidence
5
supplements
2
Primary
3
Supporting
0
Grade A
23
Studies

Primary Stack

Core supplements with strongest evidence

Mushroom extract that may support immune clearance of HPV

4 studies200 participants
200-400mg DIM or 200-400mg I3C daily

May support estrogen metabolism and cervical cell health

5 studies250 participants

Supporting Stack

Additional supplements for enhanced results
2000-4000 IU daily

Supports immune function; deficiency associated with persistent HPV

5 studies300 participants
400-800mcg daily

Deficiency associated with increased cervical dysplasia risk

5 studies300 participants
500-1000mg daily

Antioxidant immune support

4 studies200 participants

How This Protocol Works

Simple Explanation

HPV (Human Papillomavirus) is the most common sexually transmitted infection. Most infections clear on their own, but persistent infection with high-risk types can lead to cervical and other cancers.

KEY FACTS:

•Over 100 HPV types; ~40 affect genital area
•Low-risk types (6, 11): cause genital warts
•High-risk types (16, 18, others): can cause cancer
•Most infections clear within 1-2 years
•Persistent infection is the concern

CRITICAL: HPV-related conditions require medical monitoring. This protocol is SUPPORTIVE ONLY.

PREVENTION:

•HPV vaccination: Most effective prevention
•Regular Pap smears and HPV testing
•Safe sex practices

MEDICAL MANAGEMENT:

•Cervical dysplasia: monitoring, LEEP, or cone biopsy
•Genital warts: topical treatments, cryotherapy, surgery

* AHCC has preliminary evidence for immune support.

* DIM/I3C may support cervical cell health.

* Immune support with vitamins C, D, and folate.

Expected timeline: Most HPV infections clear within 1-2 years. Supplements may support immune clearance but don't replace medical monitoring.

Clinical Perspective

HPV: Most common STI. High-risk types (16, 18) cause ~70% cervical cancers. Most infections clear spontaneously; persistent infection leads to dysplasia/cancer. Screening: Pap smear + HPV co-testing. Vaccination: 9-valent covers most oncogenic types.

Management: Dysplasia requires colposcopy, biopsy, possible LEEP. Supplements: AHCC has pilot data for HPV clearance; DIM/I3C studied for cervical dysplasia with mixed results. Folate deficiency associated with increased risk. Supplements supportive - don't replace vaccination, screening, or treatment of dysplasia.

* AHCC (C-grade): Immune support. Pilot study: (PMID: 25182478). 3g daily x 6 months.

* DIM/I3C (C-grade): Estrogen/cell metabolism. Clinical trial: (PMID: 10912901). 200-400mg daily.

* Vitamin D (C-grade): Immune function. Systematic review: (PMID: 28750270). 2000-4000 IU daily.

* Folate (C-grade): Cell health. Meta-analysis: (PMID: 27450775). 400-800mcg daily.

* Vitamin C (C-grade): Immune support. Review: (PMID: 23440782). 500-1000mg daily.

Protocol notes: Vaccination: most important prevention; catch-up vaccination recommended up to age 45. Screening: Pap + HPV co-testing; screening guidelines vary by age. LEEP: loop electrosurgical excision procedure for CIN2+. Smoking: increases persistence and progression - cessation important. Immune status: immunocompromised have higher persistence rates.